Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells

FEBS Letters
H LuC Soria

Abstract

The binding of urokinase (u-PA) to its cell surface receptor (u-PAR) is critical for tumor cell invasion. Here, we report that the distribution of this binding by a u-PAR antagonist ATF-HSA inhibits in vitro the motility of endothelial cells in a dose-dependent manner. This inhibition was also observed when the cells were first stimulated with potent angiogenic factors, including bFGF or VEGF. [3H]thymidine incorporation assay demonstrated that ATF-HSA did not affect the cell proliferation. ATF-HSA was more potent than plasmin inhibitors, suggesting that it exerts its effects not solely by inhibiting the remodeling of the extracellular matrix. In fact, analysis of the cell shape change during migration revealed for the first time that its effect is related to a decrease in cell deformability. These results suggest that u-PAR antagonist may be a new approach to control angiogenesis.

References

Dec 31, 1990·Biochemical and Biophysical Research Communications·S A RabbaniD Goltzman
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·C S HEG I Goldberg
Apr 28, 1995·The Journal of Biological Chemistry·S J MandriotaM S Pepper
Apr 1, 1995·The American Journal of Physiology·N WangG Barlovatz-Meimon
Jun 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·C W CrowleyA D Levinson
Aug 1, 1993·The Journal of Cell Biology·M S PepperJ D Vassalli
Jan 1, 1993·Physiological Reviews·P Mignatti, D B Rifkin

❮ Previous
Next ❯

Citations

Jul 3, 1997·International Journal of Cancer. Journal International Du Cancer·P A AndreasenM J Duffy
Jan 22, 2003·Journal of Immunological Methods·Giovanni BernardiniMonica Napolitano
Aug 26, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A ReijerkerkM F Gebbink
Jan 19, 2002·Differentiation; Research in Biological Diversity·F ElfmanG Cunha
Apr 17, 2009·Canadian Journal of Physiology and Pharmacology·Vsevolod A TkachukYelena V Parfyonova
Mar 9, 2007·Matrix Biology : Journal of the International Society for Matrix Biology·Roman M SalasznykPaula J McKeown-Longo
Mar 30, 1999·Gynecologic Oncology·D V HorbeltN J Walker-Bupp
Jul 19, 2002·International Journal of Cancer. Journal International Du Cancer·Khalid BajouJean-Michel Foidart
Dec 19, 1998·Microscopy Research and Technique·L G Hudson, L J McCawley
Feb 12, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·I DumlerH Haller
Mar 21, 1998·Journal of Microscopy·J P RigautG Landini
Jun 25, 1998·International Journal of Cancer. Journal International Du Cancer·C HaeckelA Roessner
Apr 17, 2001·Laboratory Investigation; a Journal of Technical Methods and Pathology·B VailhéJ J Feige
Oct 23, 1997·Biochemical and Biophysical Research Communications·L DevyP Jeannesson
Mar 25, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Rishi Kumar JaiswalPramod Kumar Yadava

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.